Skip to main content


Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients

Fig. 1

LVMI and BNP levels. For the assessment of cardiac function, LVMI (a), and EF (b) were measured. LVMI and EF remained steady (mean ± SD). Patients were classified into two groups according to the BNP levels. The BNP levels in grade 1 patients (n = 14, <19.5 pg/mL) (c) remained within the normal range, and those in grade 2 patients (n = 22, ≥19.5 pg/mL) (d) gradually decreased throughout ERT period (mean ± SD)

Back to article page